Why the study?
Does idarucizumab followed by rt-PA and/or thrombectomy improve outcomes in patients with acute ischemic stroke anticoagulated with dabigatran?
Does idarucizumab followed by rt-PA and/or thrombectomy improve outcomes in patients with acute ischemic stroke anticoagulated with dabigatran?
Expert consensus provides guidance supporting the use of idarucizumab to reverse dabigatran prior to systemic thrombolysis or thrombectomy in acute ischemic stroke.
Supports expert consensus on idarucizumab before reperfusion in dabigatran stroke; leaves open need for randomized confirmation.
Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.
No takes yet. Share an insight, caveat, or question.
Diener et al. (2016) studied this question. Idarucizumab followed by rt-PA and/or thrombectomy is an expert-supported, on-label strategy for treating acute ischemic stroke in patients previously anticoagulated with dabigatran.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: